Valneva’s Strategic Pivot: Lyme Disease Vaccine Holds Key After US Setback

Valneva’s recently published 2025 annual results reveal a company at a strategic crossroads. While its core business demonstrates resilience, the complete withdrawal of its Chikungunya vaccine from the United States has created a significant commercial void. This development shifts investor focus squarely onto an upcoming milestone that is expected to define the company’s valuation in the near term.

Solid Core Business Amidst a Widening Loss

Excluding the US setback, Valneva’s commercial portfolio showed strength. The travel vaccine IXIARO recorded modest growth, generating €98.4 million of the company’s total revenue of €174.7 million. However, the net loss for the fiscal year expanded significantly to €115.2 million. This sharp increase from the prior year’s loss of €12.2 million is largely attributable to a missing one-time benefit: in 2024, the sale of a Priority Review Voucher had contributed approximately €91 million.

Concurrently, research and development expenses climbed to €85.3 million, driven by the Phase 2 Shigella program and commitments related to IXCHIQ. For the ongoing 2026 fiscal year, management is targeting product revenues between €155 million and €170 million, alongside a reduction in its cash burn rate.

The Pfizer Partnership: A Potential Valuation Catalyst

The company’s long-term prospects now hinge critically on its Lyme disease vaccine candidate, VLA15. Development partner Pfizer has already completed Phase 3 vaccinations for the pivotal efficacy study. Results from this trial are slated for release in the first half of 2026. A positive outcome would prompt Pfizer to submit applications for regulatory approval in both the US and Europe before the year ends. Success would not only trigger initial milestone payments to Valneva totaling $143 million but also secure long-term royalty streams of up to 22 percent.

Should investors sell immediately? Or is it worth buying Valneva?

IXCHIQ Withdrawal Forces Strategic Recalibration

In January 2026, Valneva’s management made a decisive move by voluntarily withdrawing applications for its Chikungunya vaccine, IXCHIQ, from the US market. This action followed a suspension by the FDA the previous August. The regulatory body acted after reports emerged linking the vaccine to more than 20 serious adverse events, including one fatal case of encephalitis.

In response, the company is attempting to offset this loss by redirecting its distribution efforts toward emerging markets. A pilot vaccination campaign, launched in Brazil in February in collaboration with the Instituto Butantan, aims to reach 20 to 40 percent of the target population there, with management reporting an encouraging initial response.

Technical and Fundamental Crossroads

Trading at €4.52 on Friday, Valneva’s shares are technically considered deeply oversold, reflected in an extremely low RSI reading of 14.7. The fundamental re-rating of the stock in the coming months depends almost entirely on the pending Phase 3 data for the Lyme disease vaccine. Positive results would pave the way for a lucrative commercial partnership. Should the data disappoint, Valneva faces a challenging future, having lost a key growth driver with the US exit of IXCHIQ.